Skip to Main Content

File this under “When is a bargain not really a bargain?”

Three months ago, the Food and Drug Administration approved a generic version of the EpiPen allergy-relief device and made a point of noting the new product from Teva Pharmaceutical (TEVA) would offer a “lower-cost option.” But Teva is not offering the sort of alternative the agency envisioned: Its $300 list price is the same that Mylan (MYL) charges for its so-called authorized generic EpiPen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • What they really need is an epi-pen with a new design. The current one is too large and awkwardly shaped to carry in your pocket without looking a bit too “happy” to see everyone 🙁

    • Auvi-Q from kaleo has a great alternative form factor. Carried in a pocket, it would look like a flip phone. Also, it will talk someone through how to use the device, in case the user is incapacitated.

      I have no interest in the company/product other than it is what my daughter carries and has had to use once. She even got to train the local EMT/fire department on the device after they showed up at her school.

    • adamis symjepi is smaller more reliable easier to use will cost less.
      Sandoz is going to launch soon.

  • May I observe that, strictly speaking, the TEVA offering is cheaper than “the EpiPen?” We shall see what impact a third entrant will cause … when there is one.

Comments are closed.